Detalhe da pesquisa
1.
Catastrophic chemotherapy toxicity leading to diagnosis of Fanconi anaemia due to FANCD1/BRCA2 during adulthood: description of an emerging phenotype.
J Med Genet
; 59(9): 912-915, 2022 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-34697207
2.
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.
Invest New Drugs
; 38(3): 844-854, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31385109
3.
Elevated levels of tumour apolipoprotein D independently predict poor outcome in breast cancer patients.
Histopathology
; 76(7): 976-987, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-31994214
4.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Lancet Oncol
; 20(9): 1239-1251, 2019 09.
Artigo
Inglês
| MEDLINE | ID: mdl-31345627
5.
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.
Lancet Oncol
; 20(7): 1023-1034, 2019 07.
Artigo
Inglês
| MEDLINE | ID: mdl-31160249
6.
Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy.
Support Care Cancer
; 27(5): 1845-1852, 2019 May.
Artigo
Inglês
| MEDLINE | ID: mdl-30178142
7.
A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability.
Support Care Cancer
; 27(4): 1497-1507, 2019 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-30392112
8.
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Lancet
; 390(10105): 1853-1862, 2017 Oct 21.
Artigo
Inglês
| MEDLINE | ID: mdl-28822576
9.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med
; 372(26): 2521-32, 2015 Jun 25.
Artigo
Inglês
| MEDLINE | ID: mdl-25891173
10.
Nivolumab in previously untreated melanoma without BRAF mutation.
N Engl J Med
; 372(4): 320-30, 2015 Jan 22.
Artigo
Inglês
| MEDLINE | ID: mdl-25399552
11.
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Lancet Oncol
; 18(9): 1202-1210, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28729151
12.
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 18(5): 611-622, 2017 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28359784
13.
Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade.
Blood
; 125(17): 2693-703, 2015 Apr 23.
Artigo
Inglês
| MEDLINE | ID: mdl-25710879
14.
A Cup of Coffee.
N Engl J Med
; 379(4): 312-313, 2018 Jul 26.
Artigo
Inglês
| MEDLINE | ID: mdl-30044929
15.
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
Histopathology
; 69(1): 25-34, 2016 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-26588661
16.
Characterization of lipid metabolism in a novel immortalized human hepatocyte cell line.
Am J Physiol Endocrinol Metab
; 309(6): E511-22, 2015 Sep 15.
Artigo
Inglês
| MEDLINE | ID: mdl-26126685
17.
Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing.
Histopathology
; 67(5): 654-63, 2015 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-25847523
18.
Ipilimumab-induced toxicities and the gastroenterologist.
J Gastroenterol Hepatol
; 30(4): 657-66, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25641691
19.
Impact of a novel breast cancer survivorship program on patient-centered outcomes: A single institutional study.
Breast J
; 26(7): 1466-1471, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32115822
20.
The Promise.
Ann Intern Med
; 171(3): 218-219, 2019 Aug 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31382286